|
Middle East Fertility Society Journal
Middle East Fertility Society
ISSN: 1110-5690
Vol. 13, Num. 1, 2008, pp. 19-21
|
Middle East Fertility Society Journal, Vol.
13, No. 1, 2008, pp. 19-21
DEBATE
The
current role of metformin in the management of infertility
Mohamed Eid, M.D.
Assist. Prof. Obs./Gyn.., Cairo University, Egypt, IVF consultant, S. Abbas IVF unit,
Jeddah, KSA, mdeid964@hotmail.com
Code Number: mf08004
Polycystic ovary
syndrome (PCOS) is associated with about 75% of all cases of anovulatory
infertility. PCOS is a very heterogeneous syndrome both in its clinical
presentation and laboratory manifestations. Hyperinsulinemia is the commonest
contributor to the state of anovulation and its reduction, by weight loss or
insulin sensitizing agents such as metformin will alone often restore ovulation
or will improve results when used in combination with other agents. Insulin is
of prime importance in the pathophysiology of PCOS. Women with PCOS exhibit a
decrease in insulin sensitivity between 30% and 40%, a deficit similar to that
seen in subjects with type 2 diabetes mellitus (1), which means that a very
large proportion of cases of anovulation and infertility is associated with
hyper-insulinemia and that the lowering of insulin concentration provides a new
therapeutic pathway. The indications for the administration of metformin to
anovulatory women with PCOS in anovulation induction program have widened, as
it seems to be difficult to predict which individuals will respond well with this
medication (2). Metformin, a biguanide, an oral hypoglycemic that does not
cause hypoglycemia in normoglycemic patients , is a non-steroidal compound that
appears to influence ovarian function both directly and indirectly. It is
metformin that has been extensively used in the management of insulin-resistant
states and that has been most thoroughly investigated for the management of
PCOS. The sum of total of its action is a decrease in insulin levels and, as a
consequence, a lowering of circulating total and free androgen levels with a
resulting improvement of the clinical sequelae of hyperandrogenism. There is
evidence that metformin also has a direct effect on androstenedione and
testosterone production by theca cells in vitro by inhibiting the expression of
steriodogenic acute regulatory (StAR) protein and 17-alpha-hydroxylase (CYP17)
(3). In the last few years a number of mostly uncontrolled short-term studies have
assessed the effects of metformin on insulin sensitivity and endocrine profile
in women with PCOS. Velazquez et al demonstrated that an improvement in insulin
sensitivity induced by 1500 mg of metformin a day for 8 weeks, leads to a
favorable change in serum concentrations of androgens, SHBG and gonadotrophins.
Metformin resulted in rapid fall insulin and the insulin to glucose ratio, with
a concurrent significant decrease in serum concentrations of testosterone (T),
free T, DHEAS and androstenedione. As far as gonadotrophin concentrations were
concerned, there was a significant decrease in LH concentrations, an increase
in FSH and a normalization of the LH: FSH ratio (4). Not all the data, however,
have been so encouraging. Two trials with essentially identical recruitment
criteria and using slightly higher doses of metformin (850 mg twice and three
times a day) over similar lengths of time, showed little or no benefit with
respect to insulin metabolism, hormone concentrations or lipid variables (5,6).
The reasons for these disagreements are unclear, but could be due to different methods
used to assess insulin action and large BMI differences (29 versus 39 kg/m²) between
study groups. In fact, it has been claimed that the ability of metformin to
alter insulin sensitivity in individuals with major obesity (≥ 40 kg/m²) is limited.
The largest prospective placebo-controlled double-blind study to date,
recruited 143 women with clomiphene-resistant anovulatory PCOS and a BMI of
>30 kg/m² (7). As regards significant weight loss and improved menstrual
cyclicity, there was no difference either in the degree of weight loss or the
degree of cycle improvement between those treated with metformin or placebo. It
is likely that a higher dose of metformin is required for very obese women with
PCOS, although data are lacking on predictive factors for response and
appropriate dosages. The evidence so far is encouraging concerning the efficiency
and safety of metformin as a single agent or in combination with clomiphene or
gonadotrophins for women with hyperinsulinemic PCOS. A recent Cochrane review has
confirmed a beneficial effect of metformin in improving rates of ovulation when
compared with placebo, and also in improving both rates of ovulation and
pregnancy when used with clomiphene citrate compared with clomiphene citrate alone
(8). The data indicate that serum concentrations of insulin and androgens
improve, although, contrary to popular belief, body weight does not fall. When
women with clomiphene-resistant PCOS were administered FSH with or without
pre-treatment with metformin for one month in an RCT, those receiving metformin
developed fewer large follicles, produced less estradiol and had fewer cycles
cancelled due to excessive follicular development (9).
The reduction of insulin
concentrations induced by metformin seemed to favor a more orderly follicular
growth in response to exogenous gonadotrophins for ovarian stimulation. Another
published study on the effects of metformin on clomiphene-resistant patients undergoing
IVF/ICSI, the results of cycles preceded by treatment with metformin were
compared retrospectively to those in which metformin was not given.
Those receiving
metformin had a decreased total number of follicles but no difference in the
mean number of oocytes retrieved. There were more mature oocytes, embryos cleaved,
increased fertilization and clinical pregnancy rates in the metformin group.
These latter two studies
would seem to confirm that both obese and insulin-resistant PCOS women have a
much greater tendency to a multi-follicular response and thus a relatively high
cycle cancellation rate on low-dose FSH stimulation in order to avoid hyperstimulation
(10). It remains to be seen whether metformin, which probably also has a direct
androgen-lowering action on the ovary, will be of help to all women with PCOS wishing
to conceive. Not only does metformin seem to be safe when continue throughout pregnancy,
but preliminary data suggest that this strategy may decrease the high miscarriage
rate usually associated with PCOS (11). It is hoped that the apparent lack of
teratogenicity of metformin that has earned it a B classification and its
beneficial effect on miscarriage rates if given throughout pregnancy will be
confirmed by future studies.
The
major concern with biguanides has been the risk of lactic acidosis. This is a
very rare and serious metabolic complication of metformin therapy, occurring
mainly in women with renal impairment, and does not appear to be a problem for
otherwise fit women with PCOS who are not frankly diabetic and who have normal
renal and liver function. The most commonly reported minor side-effects of
metformin include bloating, nausea, vomiting, flatulence and diarrhea. These
symptoms appear to be dose dependent and may be substantially minimized by
taking the tablet with meals. It is likely that an incremental dosage protocol
(500 mg up to 850 mg initially once and then twice daily) will be helpful to
acclimatize patients and minimize undesirable gastrointestinal complaints. The
use of troglitazone, the first oral thiazolidinedione approved for the
treatment of type 2 diabetes, has a beneficial effect upon insulin resistance
on PCOS (12). Unfortunately, troglitazone has been removed from the clinical
practice because of its hepatotoxicity. Later generations of
thiazolidinediones, such as rosiglitazone and pyoglitazone, may have a role in
the future. Early indications suggest a positive effect for rosiglitazone when
used alone and more so when combined with clomiphene for ovulation induction,
although there is natural reluctance to introduce them for the treatment of
women of reproductive years because of the uncertainty regarding long term
side-effects and teratogenicity (13).
CONCLUSION
At least in the short
term, the deleterious effects of hyperinsulinemia in women with PCOS are reversible.
This may be achieved by weight loss in the obese and with insulin-lowering
medication (i.e. metformin). An additional bonus is that, in the long term,
prevention of the metabolic syndrome in PCOS women by maintenance of a normal
body weight and lifestyle changes seems to be an effective measure, although
the use of insulin-lowering drugs for this purpose is still awaiting
confirmation.
End
Message: In spite of the extensive investigations on insulin sensitizers,
mainly metformin, in the management of PCOS and miscarriage over the last
decade, the pharmaceutical companies manufacturing metformin seem to be unaware
by the progress in this field to the extent that they did not include PCOS in
the indication list and did not change the firm recommendation stressing on the
contraindication of its use during pregnancy. This will lead to better patient
compliance and minimize their stress when using this medication.
REFERENCES
- Kelly CJ, Connell JM, Cameron IT, Gould GW, Lyall H. The
long term health consequences of polycystic ovary syndrome. BJOG 2000;
107:1327-38.
-
Fleming R, Hopkinson ZE, Wallace AM, Greer IA, Sattar N.
Ovarian function and metabolic factors in women with oligomenorrhea treated
with metformin in a randomized double blind placebo controlled trial. J Clin
Endocrinol Metab 2002; 87:569-74.
- Attia GR, Rainey WE, Carr BR. Metformin directly inhibits
androgen production in human theca cells. Fertil Steril 2001; 76:517-24.
-
Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ.
Metformin therapy in polycystic ovaries reduces hyperinsulinaemia, insulin
resistance, hyperandrogenaemia and systolic blood pressure, while facilitating
normal menses and pregnancy. Metabolism 1994; 43:647-54.
- Acbay O, Gundogdu S. Can metformin reduce insulin
resistance in polycystic ovary syndrome? Fertil Steril 1996; 65:946-49.
- Ehrmann DA, Cavaghan MK, Imperial J, Sturis J. Effects of
metformin on insulin secretion, insulin action and ovarian steroidogenesis in
women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82:1241-47.
- Tang T, Hayden C, Glanville J, Ballen AH. A
prospective randomized placebo controlled study of metformin in anovulatory
PCOS. Hum Reprod; 2002:853-56.
- Lord JM, Flight IHK, Norman RJ. Metformin in polycystic
ovary syndrome: systematic review and meta-analysis. Br Med J 2003; 327:951-55.
- De Leo V, Ia Marca A, Ditto A. Effects of metformin on
gonadotrophin-induced ovulation in women with polycystic ovary syndrome. Fertil
Steril 1999; 72:282-85.
- Stadtmauer LA, Toma SK, Riehl RM, Talnert LM. Metformin
treatment of patients with polycystic ovary syndrome undergoing in vitro
fertilization improves outcomes and is associated with modulation of the
insulin-like growth factors. Fertil Steril 2001; 75:505-09.
- Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Roberts KA,
Nestler JE. Effects of metformin on early pregnancy loss in the polycystic
ovary syndrome. J Clin Endocrinol Metab 2002; 87:524-29.
-
Ehrman DA, Schneider DJ, Sobel BE, Cavaghan MK.
Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis
and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol
Metab 1997; 82: 2108-116.
- Ghazeeri
G, Kutteh WH, Bryer-Ash M. Effect of rosiglitazone on spontaneous and clomiphene
citrate-induced ovulation in women with polycystic ovary syndrome. Fertil
Steril 2003; 79:562-66.
©Copyright 2008 - Middle East Fertility Society
|